THERAPY DOSSIER · th-9fd4dd70adc6

Phlorizin

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23940028 ↗2013Reported benefit

Phlorizin pretreatment reduces acute renal toxicity in a mouse model for diabetic nephropathy.

MouseChemical/toxinMalePre-treatment before streptozotocin

Model: High-dose streptozotocin-induced acute renal toxicity within a diabetic nephropathy model, with associated gastric dilatation and delayed gastric emptying

Phlorizin pre-treatment reduced renal streptozotocin uptake and resolved the direct kidney toxicity and gastric dilatation while increasing pancreatic uptake, allowing diabetic nephropathy to be induced with a single non-nephrotoxic streptozotocin dose of 70 mg/kg.

Extraction: extract · Supplied extraction confidence: 0.62. Machine-extracted fields require source verification.

Loading the evidence…